CAS 1005504-62-0

2,4-Quinazolinediamine, 5-[[1-[(2,6-dichlorophenyl)methyl]-4-piperidinyl]methoxy]-

CAS : 1005504-62-0

Formule : C₂₁H₂₃Cl₂N₅O

Degré de pureté : 95%

Couleur et forme : Solid

Masse moléculaire : 432.3462

Ref: IN-DA0002AS

Rg3039

CAS : 1005504-62-0

Rg3039

Degré de pureté : ≥98%

Masse moléculaire : 432.35g/mol

Ref: 54-BUP05919

Rg3039

CAS : 1005504-62-0

Rg3039 (PF-06687859) is a potent DcpS inhibitor. DcpS is a therapeutic target for spinal muscular atrophy (SMA). RG3039 improves motor function in SMA mice.

Formule : C₂₁H₂₃Cl₂N₅O

Degré de pureté : 98.24% - 99.58%

Couleur et forme : Solid

Masse moléculaire : 432.35

Ref: TM-T3336

RG3039

CAS : 1005504-62-0

RG3039 is a novel small molecule that has been shown to have anti-leukemic activity in vitro and in vivo. RG3039 binds to the splicing machinery of the RNA spliceosome, which is essential for regulating gene expression. It also inhibits the phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) and reduces global protein synthesis. This drug also has an effect on primary cells from patients with AML or MDS and inhibits leukemia cell proliferation. The effective dose for RG3039 was found to be around 10 μM for human cells, but this may vary depending on the cell type. The safety profile of RG3039 appears to be favorable in preclinical studies, with no signs of toxicity observed up to a dose of 50 μM.
RG3039 is a novel small molecule that has been shown to have anti-leukemic activity in vitro and in vivo. RG3039 binds to the splicing machinery of

Formule : C₂₁H₂₃Cl₂N₅O

Degré de pureté : Min. 95%

Masse moléculaire : 432.35 g/mol

Ref: 3D-FQB50462